Inhibrx Biosciences (INBX) Equity Ratio (2023 - 2025)
Inhibrx Biosciences (INBX) has disclosed Equity Ratio for 3 consecutive years, with 0.21 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio changed N/A to 0.21 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.21, a N/A change, with the full-year FY2024 number at 0.74, up 423.02% from a year prior.
- Equity Ratio was 0.21 for Q3 2025 at Inhibrx Biosciences, down from 0.32 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.85 in Q2 2024 to a low of 0.14 in Q4 2023.
- A 3-year average of 0.45 and a median of 0.32 in 2025 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: skyrocketed 423.02% in 2024, then plummeted 61.92% in 2025.
- Inhibrx Biosciences' Equity Ratio stood at 0.14 in 2023, then surged by 423.02% to 0.74 in 2024, then tumbled by 71.92% to 0.21 in 2025.
- Per Business Quant, the three most recent readings for INBX's Equity Ratio are 0.21 (Q3 2025), 0.32 (Q2 2025), and 0.74 (Q4 2024).